C4 Therapeutics Inc

+1.16 (+3.25%)
Earnings Announcements

C4 Therapeutics Posts Q3 Loss Per Share Of $0.51

Published: 11/10/2021 21:50 GMT
C4 Therapeutics Inc (CCCC) - C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results.
Q3 Loss per Share $0.51.
Q3 Revenue $8.5 Million.
C4 Therapeutics - Expects Cash, Equivalents As of Sept 30, Will Be Sufficient to Fund Planned Operating Expenses, Capex for at Least Next 24 Months.
Q3 Earnings per Share View $-0.59, Revenue View $7.6 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $7.24 Million
Adjusted EPS is expected to be -$0.57

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.